Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2013

View Archived Issues

Merck Serono funds new nonprofit EspeRare Foundation

Rare variant of CALCRL gene associated with diabetic nephropathy susceptibility

Intec Pharma receives Michael J. Fox Foundation grant

Japanese scientists disclose new vaccines for tuberculosis

NT-113, a pan-erbB inhibitor active against brain metastases in rodents

First-in-human results for ARQ-092 demonstrate disease stabilization in patients with solid tumors

Potential repurposing of old anti-inflammatory drug for tuberculosis

Bristol-Myers Squibb presents the discovery of novel HCV entry pathway inhibitors

Durect submits NDA for Posidur pain relief depot

Roche synthesizes new series of PDE10A inhibitors

Merck & Co. patents novel JAK1/JAK2 inhibitors

Rhythm begins phase II trial of RM-131 for lower GI function disorders

Bayer Intellectual Property discloses new anticancer agents

Aerocrine's Niox Mino device approved in Canada

Santhera to continue phase III Catena trial in DMD

FDA to consider accelerated approval for Sarepta Therapeutics' eteplirsen

Isis Innovation divulges new CB2 receptor agonists

Meiji Seika Pharma acquires Japanese rights to asenapine

New agents inhibiting CYP11B2 disclosed by Merck & Co.

Eli Lilly reports data from phase III trials of dulaglutide in type 2 diabetes

Authorities expand European approval of Berinert in HAE

First patient enrolled in global phase III program for Amikacin Inhale

Zymeworks achieves second milestone in collaboration with Merck & Co.

AnGes and Shionogi agree to begin phase I testing of NF-kappaB decoy oligodeoxynucleotide

Topline results reported from phase II study of GMI-1070

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...